Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00036777 · ClinicalTrials.gov registry record · Phase 1

UCN-01 and Carboplatin in Treating Patients With Advanced Solid Tumors

A Phase 1 study, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 1
Development phase
30
Enrollment target

NCT00036777: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).

NCT00036777 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00036777, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 1
Development phase
30 participants
Enrollment target

Study Summary

Phase I trial to study the effectiveness of combining UCN-01 with carboplatin in treating patients who have advanced solid tumors. UCN-01 may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining UCN-01 with carboplatin may kill more tumor cells.

Interventions

  • DRUG carboplatin
  • OTHER pharmacological study
  • DRUG 7-hydroxystaurosporine

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2002-03
Phase Phase 1

Sponsor

National Cancer Institute (NCI)

3,257 total trials

What the Registry Record Tells You About NCT00036777

The ClinicalTrials.gov registry entry for NCT00036777 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which carboplatin is the first listed.

NCT00036777 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00036777 about?

NCT00036777 is a clinical study titled "UCN-01 and Carboplatin in Treating Patients With Advanced Solid Tumors". Phase I trial to study the effectiveness of combining UCN-01 with carboplatin in treating patients who have advanced solid tumors. UCN-01 may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Drugs used in chemotherapy use different ways to stop tumor cells from...

What is the current status of trial NCT00036777?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2002-03.

What interventions are being tested in trial NCT00036777?

The interventions under investigation include: carboplatin (DRUG), pharmacological study (OTHER), 7-hydroxystaurosporine (DRUG).

Who is sponsoring clinical trial NCT00036777?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.